Antiplatelet therapy plays a crucial role in a number of cardiovascular disorders. We
currently have a range of antiplatelet agents in our armamentarium. In this review, we aim to …

Angina is the main symptom of ischemic heart disease; mirroring a mismatch between
oxygen supply and demand. Epicardial coronary stenoses are only responsible for nearly …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Ticagrelor is a platelet P2Y12 receptor inhibitor approved for use in patients with acute
coronary syndromes, coronary artery disease, and low‐moderate risk acute ischemic stroke …

Aim To assess the value of the thrombotic risk criteria proposed in the 2023 guidelines of the
European Society of Cardiology (ESC) for the management of acute coronary syndrome …

Importance Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period
of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet …

Background Clopidogrel was superior to aspirin monotherapy in secondary prevention after
percutaneous coronary intervention (PCI). Objectives The purpose of this study was to …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

Repeat coronary revascularization is a common adverse event after successful
percutaneous coronary intervention. This analysis aimed to assess the effects of ticagrelor …

Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …